Genedx Holdings Corp. · NASDAQ:WGS
Genedx — J.P. Morgan Healthcare Conference 2025
24 slides from Genedx's conference presentation, January 2025
Slide 1: GeneDx J.P. Morgan Healthcare Conference
GeneDx J.P. Morgan Healthcare Conference January 2025 San Francisco, California
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that do not relate to historical facts and events and such statements and opinions pertaining to the f
Slide 3: We envision a world where any genetic disorder is diagnosed quickly
We envision a world where any genetic disorder is diagnosed quickly to prevent disease progression and ensure long and healthy lives for all. 3
Slide 4: 1 in 10 families face an unnecessary diagnostic journey
1 in 10 families face an unnecessary diagnostic journey On average: 16 tests and 6 years before an accurate diagnosis X X X X X X X X X GeneDx can provide 1 year 3 years 5 years an answer in days 2 years 4 years X X X X X X 4 References: 1. National Orga niza tion for Rare Disord ers (NORD). Hope fo
Slide 5: The diagnostic odyssey: common, critical, and costly
The journey to an accurate diagnosis can take over six years.1 3x On their journey to a The diagnostic odyssey: diagnosis, rare disease common, critical, and costly patients will be misdiagnosed an average of three times.2 Millions of Americans with a rare 6 years disease are urgently searching for
Slide 6: Exome and genome testing offer answers sooner
Exome and genome testing offer answers sooner—leading to more effective treatments and more efficient healthcare spend Recommended by leading medical Superior diagnostic rate for many indications including: societies as a first-line test: Developmental delay Intellectual disability Epilepsy …and mor
Slide 7: Common diseases are in fact a constellation of genetic diagnoses
Common diseases are in fact a constellation of genetic diagnoses One example is epilepsy. At least 768 different genes are related to seizures. Only 43% of epilepsy genes are tested on many commercial epilepsy panels 7 Reference: Butler L. et al. Exome-based testing for patients with seizures: Advan
Slide 8: Common diseases are in fact a constellation of genetic diagnoses
Common diseases are in fact a constellation of genetic diagnoses One example is epilepsy. At least 768 different genes are related to seizures. Only 43% of epilepsy genes are tested on many commercial epilepsy panels Exome and genome sequencing checks all 768 genes 8 Reference: Butler L. et al. Exom
Slide 9: GeneDx has spent over a decade solving for the limitations of the past
GeneDx has spent over a decade solving for the limitations of the past and we're working to change the perception of exome and genome sequencing Then Now Results take months GeneDx delivers results in days or weeks Turnaround time GeneDx’s tests are accessible and Tests are prohibitively expensive w
Slide 10: Accelerating and deepening our competitive advantage with every patient
Accelerating and deepening our competitive advantage with every patient Pay it forward data strategy: the snowballing effect of data accumulated with ever patient we test drives our underlying interpretation platform to get smarter, faster, and more scalable That’s enable us to identify more than >7
Slide 11: Our data is unmatched in size, breadth, and depth
Our data is unmatched in size, breadth, and depth— making it highly infeasible for competitors to recreate • Enriched for rare disease Diagnosing even the rarest conditions for 25 years • 60% of our exomes/genomes are parent/child trios Enabling de novo findings, sequencing asymptomatic parents • 6
Slide 12: Our market opportunity is massive and poised to expand over time
Our market opportunity is massive and poised to expand over time Taking a disciplined approach entering markets as reimbursement pathways open Rolling expansion of exome/genome use cases fuels a: Historical Near Mid Long base term term term Expert geneticists Pediatric specialties (e.g., autism, epi
Slide 13: Outpatient market expansion: Fueling growth with new indications
Outpatient market expansion: Fueling growth with new indications, coverage and guidelines Today, GeneDx primarily targets epilepsy, autism and intellectual disability/developmental delay, congenital anomalies, and rare disease • We have 80% market share among genetics experts, 12% among pediatric ne
Slide 14: Inpatient (NICU) market expansion: A clear unmet need
Inpatient (NICU) market expansion: A clear unmet need, underscored by decades of earned trust and improved workflows 1 in 4 infants in U.S. NICUs likely have a genetic disorder1 • Genome testing is severely underutilized, currently ordered for <5% of children who could benefit2 • NICU orders represe
Slide 15: Genetic evidence improves the therapeutic development process
Genetic evidence is one of the most powerful tools to improve the therapeutic development process Tomorrow Today Including genetic evidence can The average therapeutic dramatically reduce cost, shorten development cycle: timelines, and improve success rates: Costs $2.6B Genetic evidence can reduce o
Slide 16: Our partnerships with biopharma companies help accelerate treatments
Our partnerships with biopharma companies help accelerate treatments— from early discovery through commercialization Our collaborations are impacting the lives of patients today: Akouos (Eli Lilly) Regeneron GeneDx partnered with Akouos to Through a data partnership with GeneDx, match patients with
Slide 17: We believe in a future where every newborn's genome is sequenced at birth
We believe in a future where every newborn’s genome is sequenced at birth Every year, thousands of newborns with actionable conditions are missed by traditional newborn screening (NBS). Federal NBS guidelines recommend testing for 37 conditions with biomarkers—measurable changes in the baby’s blood
Slide 18: GeneDx is the leader set to revolutionize newborn screening
GeneDx is the leader set to revolutionize the standard approach to today's newborn screening, enabling diagnoses before symptoms even start GeneDx has screened more newborns than any other commercial laboratory. This experience gives GeneDx a deep understanding of how to offer this testing at scale
Slide 19: Preliminary results exceeded guidance: FY 2024 revenue
Preliminary results1 exceeded guidance: FY 2024 revenue2 now expected to be $299 million (previous guidance was $284-290 million) 100 Full year 2024 revenues $299 million Quarterly Revenues by product 59% YoY $92 • up 54% YoY • includes a discrete benefit of $6.8 million in fourth 80 quarter in conn
Slide 20: Preliminary results exceeded guidance: FY 2024 adjusted gross margin
Preliminary results1 exceeded guidance: FY 2024 adjusted gross margin2 now expected to be at least 64% for full year, 68% for Q4 (previous guidance was at least 62% for full year) • Gross profit benefiting from all three of mix shift towards exome/genome, improved reimbursement and lower production
Slide 21: Multiple drivers to profitable, sustainable growth
Expanding serviceable market o New use cases/ indications / call points stemming from emerging guidelines, expanding and, secular tailwinds towards greater acceptance of exome/genome o The American Academy of Pediatrics last issued their genetic testing guidelines in 2014. An update in support of an
Slide 22: A rare opportunity to fuel seismic healthcare shifts
A rare opportunity to fuel seismic healthcare shifts From years of disease progression early interventions From unnecessary and bloated health costs streamlined economic efficiency to From generalized treatments precision medicines From diagnosing symptomatic disease universal genomic newborn screen
Slide 23: We all know the pain of being "too late"
We all know the pain of being “too late” At GeneDx, we’re making sure that children get answers right on time. We're just getting started. 23
Slide 24: Thank you
Thank you